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Letters to the EditorReply to: "Is transient elastography inaccurate in chronic
hepatitis B and non-alcoholic fatty liver disease?"To the Editor:
I appreciate the letter by Dr. Wong and colleagues on our
manuscript ‘‘Reliability of transient elastography for the detec-
tion of ﬁbrosis in non-alcoholic fatty liver disease and chronic
viral hepatitis’’ [1] because it allows me to comment more about
our results.
The manuscript aimed to describe possible factors inﬂuencing
the estimation of ﬁbrosis by transient elastography (TE) in
patients with chronic liver damage.
As is well known, elevation in serum alanine aminotransferase
(ALT) is a major confounding factor for liver stiffness measure-
ments (LSM) [2–4]. In order to analyze the accuracy of TE in
CHB and NAFLD in comparison with CHC, we excluded ‘‘a priori’’
factors known to affect TE measurement: patients with acute
liver disease, acute reactivation upon chronic liver damage, and
alcohol abuse were not included in order to avoid the inﬂuence
of acute necro-inﬂammatory edema on stiffness measurements.
Amongst 219 enrolled patients only 2 (0.9%) had ALT higher than
300 IU/L (1 CHC and 1 CHB) and 4 (0.18%) higher than 250 IU/L
(1 NAFLD, 1 CHC, 2 CHB). A stratiﬁcation of patients for ALT levels
was not available because the studied population was too homo-
geneous regarding aminotransferases. For these reasons, as
already reported in the discussion section of our manuscript,
we considered the inﬂuence of ALT on liver stiffness measure-
ment as not signiﬁcant enough in our cohort of patients.
On the other hand, our clinical observations showed that in
our patients, steatosis was a confounding factor for LSM. Com-
pared with CHC, TE was less accurate in detecting severe ﬁbrosis
in NAFLD patients, especially in those with a high degree of ste-
atosis. Fig. 4 of the paper represents the distribution of patients
with NAFLD according to ﬁbrosis and to percentage of steatosis
at biopsy vs. LSM. If we analyze this ﬁgure in detail and regroup
patients with advanced liver disease (severe ﬁbrosis/cirrhosis),
we can see that hepatic steatosis is associated with a lower
LSM within the same ﬁbrosis stage (F3–F4). Moreover, in NAFLD
patients, the stepwise multiple logistic regression analysis
showed that LSM was not an independent predictor of severe
ﬁbrosis or cirrhosis, suggesting that, in our opinion, TE is not able
to completely replace liver biopsy for the detection of ﬁbrosis in
NAFLD.
Different results reported by Wong and others from Oriental
areas [5,6] have to be interpreted while considering that the
features of the metabolic syndrome and the clinical correlatesnvasive prediction of ﬁbrosis
or:
olic fatty liver disease (NAFLD) is one of the most com-
s of liver disease worldwide. It includes a wide spec-
liver diseases, ranging from pure steatosis to
lic steatohepatitis (NASH), and eventually to liver cir-
Journal of Hepatology 2are different from European ones. However, these different
results support the concept that different steatosis features may
have signiﬁcant inﬂuences on LSM.
In conclusion our work conﬁrmed the reliability of Fibroscan
for evaluating liver ﬁbrosis in CHB or NAFLD patients, but it also
describes some limitations to be taken into account in such cate-
gories of patients. Although the correlation between LSM and
ﬁbrosis stage was demonstrated, its sensibility and speciﬁcity
were lower in CHB and NAFLD with respect to CHC patients. This
work helps the physician to interpret, in a proper manner, Fibro-
scan results in CHB and NAFLD patients with possible liver stea-
tosis or other confounding factors such as high BMI, elder age or
high ALT values.
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rhosis with its complications. The accurate evaluation of liver
ﬁbrosis in patients with NAFLD is important to identify patients
who may develop complications. The liver biopsy is still the best
available standard in the assessment of liver ﬁbrosis. However,
liver biopsy has limitations due to invasiveness, small tissue
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